The biggest investor in a nursing home chain can run but not hide from comeuppance for the chain’s alleged role in harms—including deaths—done to hundreds of patients.

Cytokinetics has secured FDA approval for aficamten, its new drug for the treatment of symptomatic obstructive HCM. Aficamten will be sold under the brand name Myqorzo. 

PAD in patients with diabetes is common and associated with an increased risk of several adverse events. A new guidance from the American College of Cardiology reviewed this topic at length, identifying areas where care needs to improve.